Replimune receives second FDA rejection for lead melanoma drug RP1
Filed April 13, 2026 · Period ending April 10, 2026 · ~1 min read
2 material changes detected in this filing.
Create a free account to read the full summary — it takes 30 seconds.
Partner
Trade REPL commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Generated by AI · Jun 3, 2026 5:46 AM